References
- Boyle JP, Honeycutt AA, Narayan KM et al. Projection of diabetes burden through 2050: impact of changing demography and disease prevalence in the U.S. Diabetes Care24, 1936–1940 (2001).
- American Diabetes Association. Economic costs of diabetes in the U.S. in 2007. Diabetes Care31, 596–615 (2008).
- Jonassen I, Havelund S, Ribel U et al. Insulin degludec: multi-hexamer formation is the underlying basis for this new generation ultra-long acting basal insulin. Diabetologia53(Suppl. 1), S388 (2010).
- Kurtzhals P, Heise T, Strauss HM et al. Multi-hexamer formation is the underlying mechanism behind the ultra-long glucose-lowering effect of insulin degludec. Presented at: American Diabetes Association 71st Scientific Sessions. San Diego, CA, USA, 24–28 June 2011.
- Nishimura E, Sørensen AR Hansen BF et al. Insulin degludec: a new ultra-long, basal insulin designed to maintain full metabolic effect while minimizing mitogenic potential. Diabetologia53(Suppl. 1), S388 (2010).
- Heise T, Hövelmann U, Nosek L, Bottcher SG, Granhall C, Haahr H. Insulin degludec has a two-fold longer half-life and a more consistent pharmacokinetic profile than insulin glargine. Presented at: American Diabetes Association 71st Scientific Sessions. San Diego, CA, USA, 24–28 June 2011.
- Heise T, Hermanski L, Nosek L et al. Insulin degludec: less pharmacodynamic variability than insulin glargine under steady state conditions. Diabetologia53(Suppl. 1), S387 (2010).
- Nosek L, Heise T, Bottcher SG, Hastrup H, Haahr H. Ultra-long acting insulin degludec has a flat and stable glucose-lowering effect. Presented at: American Diabetes Association 71st Scientific Sessions. San Diego, CA, USA, 24–28 June 2011.
- Riddle MC. The treat-to-target trial and related studies. Endocr. Pract.12(Suppl. 1), 71–79 (2006).
- Birkeland KI, Home PD, Wendisch U et al. Insulin degludec in Type 1 diabetes: a randomized controlled trial of a new-generation ultra-long-acting insulin compared with insulin glargine. Diabetes Care34, 661–665 (2011).
- Zinman B, Fulcher G, Rao PV et al. Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with Type 2 diabetes: a 16-week, randomised, open-label, Phase 2 trial. Lancet377, 924–931 (2011).
- Heller S, Francisco AMO, Pei H, Russell-Jones D. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in Type 1 diabetes. Diabetes60(Suppl. ), A19 (2011).
- Garber AJ, King AB, Francisco AMO, Endahl L, Hollander PA. Insulin degludec improves long-term glycemic control with less nocturnal hypoglycemia compared with insulin glargine: 1-year results from a randomized basal-bolus trial in people with Type 2 diabetes. Diabetes60(Suppl. 1), A20 (2011).
- Meneghini L, Atkin SL, Bain S et al. Flexible once-daily dosing of insulin degludec does not compromise glycemic control or safety compared to insulin glargine given once daily at the same time each day in people with Type 2 diabetes. Presented at: American Diabetes Association 71st Scientific Sessions. San Diego, CA, USA, 24–28 June 2011.
Website
- Internation Diabetes Federation: IDF Diabetes Atlas News. www.diabetesatlas.org/book/export/html/37